Biotech · Private company
Seqirus
Track this companyFree. Adds Seqirus to your Dealase workspace and tells you when its record changes.
Clinical trials212 recruiting or active
Pipeline programs47From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline47
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)Phase 3 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)Phase 3 · Influenza VirusClinicalTrials.gov · fetched Nov 12, 2026
- aH5N1cPhase 3 · Avian InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- aQIVPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- aQIV or aTIVPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Comparator QIVPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Comparator QIVPhase 3 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Comparator Quadrivalent Inactivated Influenza VaccinePhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Investigational aQIVcPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- licensed aQIVPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)Phase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- licensed QIVrPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)Phase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)Phase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- non-adjuvanted Quadrivalent Influenza Vaccine (QIV)Phase 3 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)Phase 3 · Influenza VirusClinicalTrials.gov · fetched Nov 12, 2026
- QIV or TIVPhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- QIVcPhase 3 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Seqirus Quadrivalent Inactivated Influenza VaccinePhase 3 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- aH5N6c on Day 1Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- aH5N6c on Day 22Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- aH5N8c on Day 1Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- aH5N8c on Day 202Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- aH5N8c on Day 22Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- aIIV4Phase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1Phase 2 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- IIV4cPhase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Investigational aIIV4cPhase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- RIV4Phase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59Phase 1 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59Phase 1 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59Phase 1 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59Phase 1 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59Phase 1 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59Phase 1 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- High dose A/H2N3c + standard dose MF59Phase 1 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- High dose A/H2N3c non-adjuvantedPhase 1 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Intermediate dose A/H2N3c + standard dose MF59Phase 1 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Low dose A/H2N3c + high dose MF59Phase 1 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Low dose A/H2N3c + standard dose MF59Phase 1 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Lowest dose A/H2N3c + high dose MF59Phase 1 · Influenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Afluria Influenza VaccineInfluenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Flucelvax Quadrivalent Influenza VaccineInfluenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
- Flucelvax Trivalent Influenza VaccineInfluenza, HumanClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials21
- Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant PatientsPHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07390968 · fetched Nov 12, 2026
- The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and OlderPHASE3 · COMPLETED · started Nov 3, 2023ClinicalTrials.gov NCT06015282 · fetched Nov 12, 2026
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgePHASE3 · COMPLETED · started Oct 23, 2023ClinicalTrials.gov NCT06087640 · fetched Nov 12, 2026
- Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 YearsRECRUITING · started Aug 17, 2023ClinicalTrials.gov NCT06029933 · fetched Nov 12, 2026
- Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in AdultsPHASE1 · COMPLETED · started Jun 15, 2023ClinicalTrials.gov NCT05875961 · fetched Nov 12, 2026
- Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in AdultsPHASE2 · COMPLETED · started Jun 7, 2023ClinicalTrials.gov NCT05874713 · fetched Nov 12, 2026
- Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of AgePHASE2 · COMPLETED · started Aug 25, 2022ClinicalTrials.gov NCT05501561 · fetched Nov 12, 2026
- A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or UnprimedPHASE2 · COMPLETED · started Jul 18, 2022ClinicalTrials.gov NCT05422326 · fetched Nov 12, 2026
- A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of AgePHASE3 · COMPLETED · started Sep 30, 2021ClinicalTrials.gov NCT05044195 · fetched Nov 12, 2026
- Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older AdultsPHASE2 · COMPLETED · started Oct 8, 2020ClinicalTrials.gov NCT04576702 · fetched Nov 12, 2026
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric SubjectsPHASE3 · COMPLETED · started Sep 6, 2019ClinicalTrials.gov NCT04074928 · fetched Nov 12, 2026
- Adjuvanted Influenza Vaccination Year 2 Follow-On SurveyCOMPLETED · started Jul 13, 2018ClinicalTrials.gov NCT03599739 · fetched Nov 12, 2026
- Phase 3 Safety and Immunogenicity Study of aQIV in Elderly AdultsPHASE3 · COMPLETED · started Oct 17, 2017ClinicalTrials.gov NCT03314662 · fetched Nov 12, 2026
- Afluria Pregnancy RegistryCOMPLETED · started Sep 8, 2017ClinicalTrials.gov NCT03442582 · fetched Nov 12, 2026
- Flucelvax (TIVc or QIVc) Pregnancy RegistryCOMPLETED · started Sep 1, 2017ClinicalTrials.gov NCT03438487 · fetched Nov 12, 2026
- A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.PHASE3 · COMPLETED · started Sep 27, 2016ClinicalTrials.gov NCT02914275 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of AgePHASE3 · COMPLETED · started Jul 11, 2016ClinicalTrials.gov NCT02839330 · fetched Nov 12, 2026
- Adjuvanted Influenza Vaccination in U.S. Nursing HomesPHASE4 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02882100 · fetched Nov 12, 2026
- Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05PHASE3 · COMPLETED · started Oct 1, 2014ClinicalTrials.gov NCT02255409 · fetched Nov 12, 2026
- Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.PHASE3 · COMPLETED · started Nov 1, 2013ClinicalTrials.gov NCT01964989 · fetched Nov 12, 2026
- Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)PHASE1 · COMPLETED · started Nov 1, 2008ClinicalTrials.gov NCT00812019 · fetched Nov 12, 2026